The former Johns Hopkins professor and researcher will take on the role as principal deputy commissioner in early 2024.
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
Among Bumpus’ priorities when she assumes the role will be “creating a new model” for the FDA’s Office of Regulatory Affairs, the branch that conducts inspections, monitors drug imports, and issues recalls, market withdrawals and safety alerts, Commissioner Robert Califf said in a memo to agency staff.
In moving from the chief scientist role to principal deputy commissioner, “Namandjé will continue to highlight and elevate our role as the premier science-based organization it truly is,” Califf wrote.
Bumpus came to the FDA from the Johns Hopkins University School of Medicine, where she was professor and chairperson of the Department of Pharmacology and Molecular Sciences. She conducted extensive research on drug metabolism and the effects of antivirals on humans and pathogens.
She joined the agency in August 2022, and since, in Califf’s words, “quickly elevated the research foundation, science and innovation that provides vital support for our public health mission.” Califf also credited her with being “a champion of plain language” in public health communication. READ MORE
by Jonathan Gardner
The agreement, signed last month, includes an upfront payment of $1bn and $400m in regulatory milestone payments. The acquisition introduces AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into GSK’s pipeline.
Vertex Pharmaceuticals and CRISPR Therapeutics have scored another regulatory approval for Casgevy (exagamglogene autotemcel) after the European Commission granted conditional marketing authorisation to the gene therapy.
US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash. CymaBay, based in the US near San Francisco, California, has developed the investigational drug seladelpar, which is currently in clinical Phase 3.